Integra Lifesciences (IART) Stock Statistics & Valuation Metrics

Integra Lifesciences has a market cap or net worth of $990.83M. The enterprise value is $3.43B.

Integra Lifesciences has 77,712,270 shares outstanding. The number of shares has decreased by -2.65% in one year.

Integra Lifesciences’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is 0.29%.

The current PE Ratio of Integra Lifesciences is -251.52. Integra Lifesciences’s PEG ratio is 2.28.

In the last 12 months, Integra Lifesciences had revenue of 1.61B and earned -6.94M in profits. Earnings per share was -0.09.

In the last 12 months, operating cash flow was 102.37M and capital expenditures -98.91M, giving a free cash flow of 3.46M billion.

Integra Lifesciences pays an annual dividend of $3.184, resulting in a dividend yield of ―

Integra Lifesciences upcoming earnings date is Jul 23, 2025, TBA Not Confirmed.

Integra Lifesciences as a current ratio of 1.17, with Debt / Equity ratio of 0.00%

In the past 12 months, Integra Lifesciences has paid -11.29M in taxes.

Integra Lifesciences EV to EBITDA ratio is 18.03, with an EV/FCF ratio of 139.59.

Integra Lifesciences has $273.30M in cash and marketable securities with $186.38M in debt, giving a net cash position of -$273.30M billion.

Gross margin is 65.53%, with operating margin of 1.76%, and net profit margin of -0.43%.

The average price target for Integra Lifesciences is $20.50, which is 11.43% higher than the current price. The consensus rating is Hold